Welcome to the POMALYST REMS™ program
POMALYST® (pomalidomide) is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy. Approval is based on response rate. Clinical benefit, such as improvement in survival or symptoms, has not been verified.
Important information about POMALYST and the POMALYST Risk Evaluation
and Mitigation Strategy (REMS)™ program
-
POMALYST is contraindicated in pregnant females and females capable of becoming pregnant. Females of reproductive potential may be treated with POMALYST provided adequate precautions are taken to avoid pregnancy
-
To avoid embryo-fetal exposure, POMALYST is only available under a restricted distribution program called "POMALYST REMS™"
-
Only prescribers and pharmacies certified by the POMALYST REMS™ program can prescribe and dispense POMALYST to patients who are enrolled and meet all the conditions of the POMALYST REMS™ program
The goals of the POMALYST risk evaluation and mitigation strategy are as follows:
-
To prevent the risk of embryo-fetal exposure to POMALYST
-
To inform prescribers, patients, and pharmacists on the serious risks and safe-use conditions for POMALYST
POMALYST® is a registered trademark of Celgene Corporation.
POMALYST REMS™ is a trademark of Celgene Corporation.
©2013 year of origin. Celgene Corporation, www.celgene.com.
This website is intended for residents of the United States only.
